viewe-Therapeutics PLC

Pharma giant Novo Nordisk extends contract with e-Therapeutics

Headlines from the Proactive Investors UK newsroom.

E-therapeutics (LON:ETX) has extended its collaboration with Novo Nordisk to investigate new therapeutic approaches for type 2 diabetes. It is the first research agreement for e-therapeutics' new functional genomics technology.

Eland Oil (LON:ELA) has started production at a second field on its OML 40 license in Nigeria. Production will rise to approximately 12,000 barrels of oil per day from two wells over the next seven days.

UK Oil and Gas (LON:UKOG) says testing of the deeper Kimmerdige levels of the Weald Basin at Horse Hill flowed at between 200-266 barrels per day.  The test indicates potential production of at least 450 barrels daily from both levels at Horse Hill.

Shell’s second quarter profit tumbled 50% due to lower oil, gas and LNG prices while margins came under pressure in chemicals and refining.  The Anglo-Dutch giant only held its quarterly dividend.

Barclays also saw a weaker trend in its latest half year with underlying profits dropping by 16%.

Rio Tinto shareholders are to get a special dividend of US$1bn on top of an interim dividend of $2.5bn after strong iron ore prices boosted its first half. 

Quick facts: e-Therapeutics PLC

Price: 12 GBX

Market: AIM
Market Cap: £38.69 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics PLC named herein, including the promotion by the Company of e-Therapeutics PLC in any Content on the Site, the Company receives...


2 min read